Form 4: Sabra Health Care Executive Sells Shares

Sabra Health Care REIT's Executive VP & CAO, Jessica Flores, sold 15,231 shares of common stock for approximately $19.86 per share.

Summary

• Jessica Flores, Executive VP & CAO of Sabra Health Care REIT, Inc. (SBRA), sold 15,231 shares of common stock.
• The transaction occurred on March 25, 2026, and was executed pursuant to a Rule 10b5-1 plan.
• The shares were sold at a weighted average price of $19.86 per share, with individual transaction prices ranging from $19.85 to $19.89.
• Following the sale, Jessica Flores beneficially owns 71,709 shares, which includes 25,527 stock units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, the indication that it was executed under a Rule 10b5-1 plan suggests a pre-arranged disposition rather than a reaction to new information, mitigating potential negative sentiment.

Positives

• The sale was executed pursuant to a Rule 10b5-1 plan, indicating a pre-scheduled transaction rather than an opportunistic sale based on new information.

Negatives

• An insider, the Executive VP & CAO, sold 15,231 shares of common stock, reducing her direct beneficial ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider sales, even when pre-planned via a 10b5-1 plan, are routinely monitored by investors for insights into management's perception of future stock performance. In the healthcare REIT sector, such sales can sometimes be interpreted in the context of broader industry trends, such as interest rate sensitivity or specific sub-sector performance, though this filing provides no direct link.

Stakeholder Impact

• Shareholders may interpret the insider sale as a slight negative signal, though this is mitigated by the disclosure that the transaction was part of a pre-arranged Rule 10b5-1 plan.

Key Dates

Recommendation

The insider sale, while significant in volume, was conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not based on new, adverse information. This mitigates the typical negative signal of an insider sale, leading to a neutral 'hold' recommendation rather than a 'sell.' Investors should monitor future filings and company performance for more definitive signals.

Keywords

Sabra Health Care REIT, SBRA, Insider Trading, Form 4, Stock Sale, Jessica Flores, Executive VP & CAO, Healthcare REIT, Real Estate Investment Trust